Senate inquiry into Avandia safety puts GSK in the hot seat
This article was originally published in Scrip
Executive Summary
A US Senate inquiry into GlaxoSmithKline's Avandia (rosiglitazone) has found that the drug is needlessly hazardous and has accused the UK company of deliberately misleading physicians and the public over the safety profile of its much-beleaguered, once-blockbuster anti-diabetic.